BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32654071)

  • 1. Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer.
    Wang FT; Wang H; Wang QW; Pan MS; Li XP; Sun W; Fan YZ
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):221-232. PubMed ID: 32654071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
    Shi Y; Fan Y; Hu Y; Jing J; Wang C; Wu Y; Geng Q; Dong X; Li E; Dong D
    J Cell Mol Med; 2020 Jan; 24(1):760-771. PubMed ID: 31762191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
    Yu Y; Wang J; Xia N; Li B; Jiang X
    Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
    Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
    J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
    Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species.
    Fu Z; Cheng X; Kuang J; Feng H; Chen L; Liang J; Shen X; Yuen S; Peng C; Shen B; Jin Z; Qiu W
    Mol Oncol; 2018 Apr; 12(4):529-544. PubMed ID: 29453806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
    Wang W; Hu Z; Huang Y; Zheng H; Sun Q; Yang Q; Zhang Y; Zhang L; Wang W
    Biomed Res Int; 2019; 2019():9205851. PubMed ID: 31019975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
    Zhang DC; Liu JL; Ding YB; Xia JG; Chen GY
    Acta Pharmacol Sin; 2013 Feb; 34(2):301-8. PubMed ID: 23274410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.
    Zhang GF; Wu JC; Wang HY; Jiang WD; Qiu L
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32869841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α.
    Gao H; Xie J; Peng J; Han Y; Jiang Q; Han M; Wang C
    Exp Cell Res; 2015 Mar; 332(2):236-46. PubMed ID: 25499970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
    Mita Y; Ajiki T; Kamigaki T; Okazaki T; Hori H; Horiuchi H; Hirata K; Fujita T; Fujimori T; Kuroda Y
    Ann Surg Oncol; 2007 Apr; 14(4):1374-80. PubMed ID: 17235714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy.
    Xu S; Jiang C; Lin R; Wang X; Hu X; Chen W; Chen X; Chen T
    J Exp Clin Cancer Res; 2021 Nov; 40(1):373. PubMed ID: 34823564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOAT1 in gallbladder cancer: Clinicopathological significance and avasimibe therapeutics.
    Hong Y; Abudukeremu X; She F; Chen Y
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23733. PubMed ID: 38770938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
    Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
    Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
    Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
    Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine.
    Yang C; Xu M; Shen HJ; Zhu HY; Li F; He M; Chen T; Wang J; Shi WJ; Ji F
    Int J Clin Exp Pathol; 2014; 7(2):521-8. PubMed ID: 24551272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
    Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
    Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
    Hatami E; Nagesh PKB; Jaggi M; Chauhan SC; Yallapu MM
    Eur J Pharmacol; 2020 Dec; 888():173486. PubMed ID: 32805254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.